Prot #MVT-601-035: An International Phase 3 Double-Blind, Placebo-controlled, Randomized Withdrawal Study of Relugolix Co-administered with Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids

Project: Research project

StatusActive
Effective start/end date9/18/199/18/22

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #MVT-601-035)
  • Myovant Sciences, Inc. (Prot #MVT-601-035)